|
Volumn 1, Issue 1, 2002, Pages 13-15
|
Disabling Abl - Perspectives on Abl kinase regulation and cancer therapeutics
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABELSON KINASE;
BCR ABL PROTEIN;
IMATINIB;
PROTEIN TYROSINE KINASE;
STEM CELL FACTOR RECEPTOR;
ANTINEOPLASTIC AGENT;
BCR ABL TYROSINE KINASE;
BCR-ABL TYROSINE KINASE;
ENZYME INHIBITOR;
PIPERAZINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
CANCER PATIENT;
CANCER RELAPSE;
CANCER STAGING;
CANCER THERAPY;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
DIMERIZATION;
ENZYME ACTIVITY;
ENZYME INHIBITION;
ENZYME REGULATION;
GENE MUTATION;
HUMAN;
PRIORITY JOURNAL;
PROTEIN BINDING;
PROTEIN DOMAIN;
PROTEIN EXPRESSION;
PROTEIN MOTIF;
SHORT SURVEY;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
BINDING SITE;
DRUG ANTAGONISM;
ENZYMOLOGY;
PHYSIOLOGY;
PROTEIN TERTIARY STRUCTURE;
REVIEW;
ANTINEOPLASTIC AGENTS;
BINDING SITES;
ENZYME INHIBITORS;
HUMANS;
LEUKEMIA, MYELOID, CHRONIC;
PIPERAZINES;
PROTEIN STRUCTURE, TERTIARY;
PROTEIN-TYROSINE KINASES;
PYRIMIDINES;
|
EID: 0036463987
PISSN: 15356108
EISSN: None
Source Type: Journal
DOI: 10.1016/S1535-6108(02)00022-3 Document Type: Review |
Times cited : (45)
|
References (17)
|